The purpose of this study is to evaluate the effectiveness of IMG-7289 as a treatment option for essential thrombocythemia (ET) that has not responded adequately to at least one current standard therapy. IMG-7289 is an orally administered LSD1 inhibitor aimed at suppressing disease cells.
Study participants will be monitored for changes in blood counts and disease related symptoms, as well as how they tolerate IMG-7289 and how doses impact each patient’s disease.
This is an open-label study, which means both you and your study doctor know what dose of IMG-7289 you are receiving, and the initial treatment period is 24 weeks long consisting of 10 study visits.
IMG-7289 is considered investigational, which means that it has not been approved by the US Food and Drug Administration (FDA).
Detailed eligibility criteria will be reviewed with the study team.